Compare
Shuttle Pharmaceuticals Holdings, Inc. vs Traws Pharma, Inc. vs Longeveron Inc. vs Genprex, Inc.
| Latest fiscal year | Shuttle Pharmaceuticals Holdings, Inc. SHPH | Traws Pharma, Inc. TRAWRevenue covers only part of its income (partial revenue) | Longeveron Inc. LGVN | Genprex, Inc. GNPX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $1.20M | n/a |
| Revenue growth (YoY) | n/a | n/a | -49.9% | n/a |
| Gross margin | n/a | n/a | 67.0% | n/a |
| Operating margin | n/a | n/a | n/m | n/a |
| Net margin | n/a | n/a | n/m | n/a |
| Net income | -$11.72M | $9.17M | -$22.70M | -$16.23M |
| EPS (Diluted) | -$7.16 | $0.82 | -$1.29 | n/a |
| Operating cash flow | -$9.48M | -$18.18M | -$18.64M | -$15.31M |
| Free cash flow | n/a | -$20.77M | -$18.89M | n/a |
| Cash & equivalents | $334.0K | n/a | $4.66M | $7.83M |
| Total assets | $10.48M | $10.62M | $10.26M | $10.16M |
| Total liabilities | $8.22M | $11.25M | $4.59M | $2.20M |
| Shareholders' equity | $2.25M | -$629.0K | $5.67M | $7.96M |
| Return on year-end equity | -519.9% | n/a | -400.1% | -203.8% |
| Shares outstanding | 2.02M | 9.07M | n/a | 3.29M |
Revenue, most recent five fiscal years
| Fiscal year | Shuttle Pharmaceuticals Holdings, Inc. | Traws Pharma, Inc. | Longeveron Inc. | Genprex, Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | $1.20M Ended 2025-12-31 | $0 Ended 2024-12-31 |
| 1 year earlier | n/a | n/a | $2.39M Ended 2024-12-31 | $0 Ended 2023-12-31 |
| 2 years earlier | n/a | n/a | $709.0K Ended 2023-12-31 | $0 Ended 2022-12-31 |
| 3 years earlier | n/a | n/a | $1.22M Ended 2022-12-31 | $0 Ended 2021-12-31 |
| 4 years earlier | n/a | n/a | $1.31M Ended 2021-12-31 | $0 Ended 2020-12-31 |